...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Statins, bone metabolism and treatment of bone catabolic diseases
【24h】

Statins, bone metabolism and treatment of bone catabolic diseases

机译:他汀类药物,骨骼代谢和骨代谢疾病的治疗

获取原文
获取原文并翻译 | 示例
           

摘要

The discovery that statins had bone anabolic properties initiated many investigations into their use for treatment of bone catabolic diseases, such as osteoporosis. This paper reviews the molecular basis of statin's role in bone metabolism, and animal and human studies on the impact of systemic statins on osteoporosis-induced bone fracture incidence and healing, and on bone density. Limitations of systemic statins are described along with alternative dosing strategies, including local applications and bone-targeting systemic preparations. The principal findings of this review are: (1) traditional oral dosing with statins results in minimal efficacy in the treatment of osteoporosis; (2) local applications of statins show promise in the treatment of accessible bony defects, such as periodontitis; and (3) systemically administered statins which can target bone or inflammation near bone may be the safest and most effective strategy in the treatment of osseous deficiencies.
机译:他汀类药物具有骨合成代谢特性的发现引发了对其用于治疗骨分解代谢疾病(例如骨质疏松症)的许多研究。本文综述了他汀类药物在骨骼代谢中作用的分子基础,以及动物和人类对全身他汀类药物对骨质疏松症引起的骨折发生和愈合以及骨密度影响的研究。描述了全身他汀类药物的局限性以及其他给药策略,包括局部应用和靶向骨的全身制剂。该评价的主要发现是:(1)传统的他汀类药物口服治疗导致骨质疏松症的疗效最低; (2)他汀类药物的局部应用在治疗可及的骨缺损(如牙周炎)方面显示出希望。 (3)可以针对骨骼或骨骼附近炎症的全身用药的他汀类药物可能是治疗骨缺乏症最安全,最有效的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号